Stimulating pharmaceutical research and development for neglected diseases

被引:24
|
作者
Mrazek, MF [1 ]
Mossialos, E [1 ]
机构
[1] Univ London London Sch Econ & Polit Sci, LSE Hlth & Social Care, London WC2A 2AE, England
关键词
neglected diseases; pharmaceutical research and development; public-private partnerships; PUBLIC-PRIVATE PARTNERSHIPS; INFECTIOUS-DISEASES; COUNTRIES; DRUGS; TUBERCULOSIS; MALARIA; WORLD;
D O I
10.1016/S0168-8510(02)00138-0
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
New vaccines and drug treatments are needed for tackling the neglected diseases (NDs) of poor countries. These diseases are associated with high levels of mortality and/or morbidity, but lack appropriate vaccines and drug treatments because of bacterial resistance, toxicity, long-treatment protocols, problems with administration or because none are available. Current initiatives directed at research and development (R&D) of NDs are being led predominantly by the governmental, inter-governmental and private not-for-profit sectors implemented by way of public-private partnerships. Push and pull mechanisms targeted at the pharmaceutical industry have also been proposed as another way to stimulate RD of NDs; however, these should be viewed with some caution. Stimulating R&D for NDs is important as part of a wider long-term public health strategy and must be addressed simultaneously with resolving more immediate problems of access to medicines and health system sustainability in less developed countries. (C) 2002 Published by Elsevier Science Ireland Ltd.
引用
收藏
页码:75 / 88
页数:14
相关论文
共 50 条
  • [1] News and Views Stimulating Research and Development of Pharmaceutical Products for Neglected Diseases
    Stirner, Beatrice
    EUROPEAN JOURNAL OF HEALTH LAW, 2008, 15 (04) : 391 - 409
  • [2] Perspectives on stimulating industrial research and development for neglected infectious diseases
    Webber, D
    Kremer, M
    BULLETIN OF THE WORLD HEALTH ORGANIZATION, 2001, 79 (08) : 735 - 741
  • [3] Bibliometric study of research and development for neglected diseases in the BRICS
    Bai, Jing
    Li, Wei
    Huang, Yang-Mu
    Guo, Yan
    INFECTIOUS DISEASES OF POVERTY, 2016, 5
  • [4] The role of Product Development Partnerships in research and development for neglected diseases
    Moran, M.
    Guzman, J.
    Ropars, A. L.
    Illmer, A.
    INTERNATIONAL HEALTH, 2010, 2 (02): : 114 - 122
  • [5] Bibliometric study of research and development for neglected diseases in the BRICS
    Jing Bai
    Wei Li
    Yang-Mu Huang
    Yan Guo
    Infectious Diseases of Poverty, 5
  • [6] Responsibility of the pharmaceutical industry on research investment in neglected diseases. Proposal for improvement
    Casas Roma, Xavier
    DAIMON-REVISTA INTERNACIONAL DE FILOSOFIA, 2015, (64): : 117 - 132
  • [7] Fostering incentives for research, development, and delivery of interventions for neglected tropical diseases: lessons from malaria
    Berdud, Mikel
    Towse, Adrian
    Kettler, Hannah
    OXFORD REVIEW OF ECONOMIC POLICY, 2016, 32 (01) : 64 - 87
  • [8] Neglected Tropical Diseases: A Systematic Evaluation of Research Capacity in Nigeria
    Okorie, Patricia N.
    Bockarie, Moses J.
    Molyneux, David H.
    Kelly-Hope, Louise A.
    PLOS NEGLECTED TROPICAL DISEASES, 2014, 8 (08):
  • [9] Editorial: Developing drugs for neglected diseases
    White, NJ
    TROPICAL MEDICINE & INTERNATIONAL HEALTH, 2006, 11 (04) : 383 - 384
  • [10] Social sciences research in neglected tropical diseases 1: the ongoing neglect in the neglected tropical diseases
    Allotey, Pascale
    Reidpath, Daniel D.
    Pokhrel, Subhash
    HEALTH RESEARCH POLICY AND SYSTEMS, 2010, 8